If you’re somewhat versed in the tech world, you have probably heard terms like semiconductors, quantum computing and bioelectronics, and their potential to change the world. While some companies might suggest that these have a long way to go before they are usable by the layman, Archer Materials is readying to inject them into our everyday lives, thus giving investors the front-row seat to the next frontier of technology.
Australian semiconductor company Archer Materials (ASX: AXE) stands on the brink of a transformative 2024, looking forward to tech milestones progressing the development of its quantum chip, and the anticipated delivery of its biochip sensors through manufacturing runs by its foundry partners worldwide.
Archer validated previous Biochip graphene field effect transistor (gFET) designs in collaboration with German and Dutch foundries. This was followed by the dispatching of its latest Biochip iteration to a semiconductor foundry in Spain, for fabrication edging it towards the first prototypes of its kind.
The decision to work with a Spanish foundry for the new Biochip design aims to leverage expertise and facilities, while the foundry ISO 13485 certification highlights potential future medical manufacturing partnerships, a key aspect of Archer’s Biochip development strategy.
Archer’s lab-on-a-chip Biochip technology aims to enable testing for analytes that hint at the existence of disease in multiple liquid samples on one microchip. This types of technology promises to be cost-effective, efficient and, perhaps most importantly, a timely development. In recent years, COVID-19 unearthed the cracks in global healthcare systems. As per the World Health Organisation (WHO), in 2023, highlighted that over half of the world’s population still cannot access universal health services. The consequences of this disparity in access is that consequences stretch beyond individual well-being, affecting overall communities and worsening socioeconomic differences.
Biochip technologies have the potential to create a more equitable world.
Archer’s Biochip technology merges graphene with lab-on-a-chip platforms for advanced medical testing. Tiny, miniaturised devices that could potentially be integrated into modern day devices. The crucial element in this development is bringing together electronics device manufacturing and biochemistry. Biochips benefit from the miniaturisation of devices, potentially allowing effective diagnostics by integrating various lab functions on a single chip to process, detect, and analyse biological samples.
Archer’s intellectual property portfolio has an emerging theme of next-generation technology for wide-scale access. The company is developing a quantum chip to operate in mobile devices for applications in quantum computing, with patents protecting this technology across Asia, Europe, and the US. However, the company’s quantum leaps have recently seen it advancing from lab-to-fab in its Biochip manufacturing, capturing the attention of investors and industry observers alike.
The company is gearing up to deliver Biochip manufacturing runs from multiple foundry partners across the globe, marking a crucial step forward towards commercialisation. The delivery of Biochip manufacturing runs showcases the scalability and foundry readiness of Archer’s technology.
Moreover, Archer has positioned itself strategically in the global arena in collaboration with the World Economic Forum. Last year, it became the first Australian company to join forces with the Forum’s Centre for the Fourth Industrial Revolution (C4IR). This partnership, alongside Archer’s existing alliances with top-tier manufacturers and research hubs, strengthens its position in securing future manufacturing capabilities and supporting technological advancements.
Archer actively participated in the World Economic Forum strategic white papers, including “The Quantum Economy Blueprint”, which aims to establish a fair quantum ecosystem research on safeguarding global value chains from disruptions.
Archer is approaching the year emphasising the development of its quantum processor and Biochip while cooperating with organisations that could help the company potentially bring its technologies to global markets. Taking note of its tech prowess, one could assuredly say that it is well on the way towards realising this goal.
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
- Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
- Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
- CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
Leave a Comment
You must be logged in to post a comment.